Chronic Heart Failure in Older Adults

Medical Clinics of North America

Volumn 95, Issue 3, 2011, Pages 439-461

  Ahmed, Ali ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Ejection fraction; Etiology; Fluid volume assessment; Geriatric heart failure; Treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETENIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; LOOP DIURETIC AGENT; TORASEMIDE; UNCLASSIFIED DRUG;

BODY FLUID; CLINICAL PROTOCOL; DIAGNOSTIC TEST; HEART EJECTION FRACTION; HEART FAILURE; HEART SURGERY; HUMAN; HYPOKALEMIA; PRIORITY JOURNAL; REVIEW; VENOUS PRESSURE;

AGED; AGED, 80 AND OVER; BODY FLUIDS; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; ECHOCARDIOGRAPHY; FEMALE; GERIATRIC ASSESSMENT; HEART FAILURE; HUMANS; JUGULAR VEINS; MALE; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 79955619877     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2011.02.001     Document Type: Review

References (57)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2010, 123(4):e18-e209.
2. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:948-954.
3. Ahmed A. Clinical manifestations, diagnostic assessment, and etiology of heart failure in older adults. Clin Geriatr Med 2007, 23:11-30.
4. Fonarow G.C., Stough W.G., Abraham W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007, 50:768-777.
5. Aronow W.S. Drug treatment of systolic and of diastolic heart failure in elderly persons. J Gerontol A Biol Sci Med Sci 2005, 60:1597-1605.
6. Ahmed A. American College of Cardiology/American Heart Association chronic heart failure evaluation and management guidelines: relevance to the geriatric practice. J Am Geriatr Soc 2003, 51:123-126.
7. Ahmed A. DEFEAT heart failure: clinical manifestations, diagnostic assessment, and etiology of geriatric heart failure. Heart Fail Clin 2007, 3:389-402.
8. Ahmed A., Jones L., Hays C.I. DEFEAT heart failure: assessment and management of heart failure in nursing homes made easy. J Am Med Dir Assoc 2008, 9:383-389.
9. Gottdiener J.S., McClelland R.L., Marshall R., et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The cardiovascular health study. Ann Intern Med 2002, 137:631-639.
10. Kitzman D.W., Gardin J.M., Gottdiener J.S., et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS research group. Cardiovascular health study. Am J Cardiol 2001, 87:413-419.
11. Kitzman D.W., Little W.C., Brubaker P.H., et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002, 288:2144-2150.
12. Ekundayo O.J., Howard V.J., Safford M.M., et al. Value of orthopnea, paroxysmal nocturnal dyspnea, and medications in prospective population studies of incident heart failure. Am J Cardiol 2009, 104:259-264.
13. Butman S.M., Ewy G.A., Standen J.R., et al. Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. J Am Coll Cardiol 1993, 22:968-974.
14. Drazner M.H., Rame J.E., Stevenson L.W., et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001, 345:574-581.
15. Curtis J.P., Selter J.G., Wang Y., et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005, 165:55-61.
16. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004, 350:647-654.
17. Vinayak A.G., Levitt J., Gehlbach B., et al. Usefulness of the external jugular vein examination in detecting abnormal central venous pressure in critically ill patients. Arch Intern Med 2006, 166:2132-2137.
18. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
19. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
20. Nieminen M.S., Bohm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European Society of Cardiology. Eur Heart J 2005, 26:384-416.
21. Seth R., Magner P., Matzinger F., et al. How far is the sternal angle from the mid-right atrium?. J Gen Intern Med 2002, 17:852-856.
22. Sochowski R.A., Dubbin J.D., Naqvi S.Z. Clinical and hemodynamic assessment of the hepatojugular reflux. Am J Cardiol 1990, 66:1002-1006.
23. Ahmed A. Association of diastolic dysfunction and outcomes in ambulatory older adults with chronic heart failure. J Gerontol A Biol Sci Med Sci 2005, 60:1339-1344.
24. Ahmed A., Husain A., Love T.E., et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006, 27:1431-1439.
25. Ahmed A., Young J.B., Love T.E., et al. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol 2008, 125:246-253.
26. Alper A.B., Campbell R.C., Anker S.D., et al. A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol 2009, 137:1-8.
27. Ahmed A., Zannad F., Love T.E., et al. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007, 28:1334-1343.
28. Bowling C.B., Pitt B., Ahmed M.I., et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 2010, 3:253-260.
29. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
30. Lopez B., Querejeta R., Gonzalez A., et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004, 43:2028-2035.
31. Cosin J., Diez J., TORIC investigators Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002, 4:507-513.
32. Murray M.D., Deer M.M., Ferguson J.A., et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001, 111:513-520.
33. Ahmed M.I., Ekundayo O.J., Mujib M., et al. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol 2010, 144:383-388.
34. Ekundayo O.J., Adamopoulos C., Ahmed M.I., et al. Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study. Int J Cardiol 2010, 141:167-174.
35. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999, 341:709-717.
36. The Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533.
37. Ahmed A., Rich M.W., Love T.E., et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006, 27:178-186.
38. Ahmed A., Rich M.W., Fleg J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006, 114:397-403.
39. Ahmed A., Pitt B., Rahimtoola S.H., et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol 2008, 123:138-146.
40. Ahmed A. Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. J Gerontol A Biol Sci Med Sci 2007, 62:323-329.
41. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
42. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task force on practice guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
43. Ahmed A., Dell'Italia L.J. Use of beta-blockers in older adults with chronic heart failure. Am J Med Sci 2004, 328:100-111.
44. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
45. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
46. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467.
47. Zile M.R., Gaasch W.H., Anand I.S., et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in heart failure with preserved ejection fraction study (I-Preserve) trial. Circulation 2010, 121:1393-1405.
48. Cleland J.G., Tendera M., Adamus J., et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail 1999, 1:211-217.
49. Cleland J.G., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
50. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003, 362:777-781.
51. Flather M.D., Shibata M.C., Coats A.J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215-225.
52. Ahmed A., Young J.B., Gheorghiade M. The underuse of digoxin in heart failure, and approaches to appropriate use. CMAJ 2007, 176:641-643.
53. Tang A.S., Wells G.A., Talajic M., et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010, 363:2385-2395.
54. Swindle J.P., Rich M.W., McCann P., et al. Implantable cardiac device procedures in older patients: use and in-hospital outcomes. Arch Intern Med 2010, 170:631-637.
55. Kusumoto F. Best clinical practice: art, science, or both?: comment on "implantable cardiac device procedures in older patients" Arch Intern Med 2010, 170:638-639.
56. Nichol G., Kaul P., Huszti E., et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004, 141:343-351.
57. Zellner R.A., Aulisio M.P., Lewis W.R. Should implantable cardioverter-defibrillators and permanent pacemakers in patients with terminal illness be deactivated? Deactivating permanent pacemaker in patients with terminal illness. Patient autonomy is paramount. Circ Arrhythm Electrophysiol 2009, 2:340-344.